Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy
Élie Choufani(Boston Medical Center), David C. Seldin(Boston University), Karen Quillen(Boston University), Vaishali Sanchorawala(Boston Medical Center), Timothy J. Ernst(Boston Medical Center), Daniel G. Wright(University of Washington), Martha Skinner(Boston University)
Cited by 230
Related Papers
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550
Amyloidosis: Pathogenesis and New Therapeutic Options
|Journal of Clinical Oncology|2011|508